Abstract
Chlamydia pneumoniae is known to cause acute respiratory tract infections in the non-immunocompromised population. So far, no data about the incidence of chlamydial infections in neutropenic patients are available. Macrolide antibiotics are not considered to be first-line treatment options in neutropenic patients. We report the case of a patient with Hodgkin's disease who developed C. pneumoniae pneumonia during mild neutropenia. C. pneumoniae should be considered as a causative agent of pneumonia in neutropenic patients.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Aza Compounds / therapeutic use
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Chlamydophila Infections / drug therapy
-
Chlamydophila Infections / etiology*
-
Chlamydophila Infections / microbiology
-
Chlamydophila pneumoniae / isolation & purification*
-
Dacarbazine / administration & dosage
-
Dacarbazine / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Drug Therapy, Combination / therapeutic use
-
Female
-
Fluoroquinolones
-
Hodgkin Disease / complications*
-
Hodgkin Disease / drug therapy
-
Humans
-
Imipenem / therapeutic use
-
Immunocompromised Host
-
Moxifloxacin
-
Neutropenia / chemically induced
-
Neutropenia / complications*
-
Pneumonia, Bacterial / drug therapy
-
Pneumonia, Bacterial / etiology*
-
Pneumonia, Bacterial / microbiology
-
Quinolines / therapeutic use
-
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
-
Vancomycin / therapeutic use
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Aza Compounds
-
Fluoroquinolones
-
Quinolines
-
Bleomycin
-
Vincristine
-
Vancomycin
-
Imipenem
-
Dacarbazine
-
Doxorubicin
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Moxifloxacin